Corporate ActionAug 3, 2026, 05:19 PM
Moleculin Biotech Raises $9.3M in Public Offering
AI Summary
Moleculin Biotech, Inc. completed a public offering on August 3, 2026, raising approximately $9.3 million in gross proceeds. The offering included 12,376,667 shares of common stock (or pre-funded warrants) and Series I Common Stock Purchase Warrants to acquire up to 37,130,001 shares. Roth Capital Partners, LLC acted as the placement agent. The net proceeds will be used to advance Annamycin through clinical development and for working capital.
Key Highlights
- Gross proceeds from the offering were approximately $9.3 million.
- Offering included 12,376,667 shares of common stock or pre-funded warrants.
- Series I Common Warrants issued to purchase up to 37,130,001 shares.
- Combined public offering price was $0.75 per share/pre-funded warrant and accompanying Common Warrant.
- Common Warrants are exercisable at $0.75 per share and expire in five years.
- Pre-Funded Warrants are exercisable at $0.001 per share.
- Company agreed to a 45-day lock-up period for new equity issuances.
- Net proceeds will fund Annamycin clinical development and working capital.
- Company agreed to a 180-day lock-up period for Variable Rate Transactions.
Price Impact
More from MBRX